ApramycinAlternative Names: Apramycin sulfate; RP 41578
Latest Information Update: 04 Jul 2002
At a glance
- Originator Aventis
- Class Antibacterials
- Mechanism of Action Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Jun 2000 New profile
- 13 Jun 2000 Preclinical development for Cancer in France (Unknown route)